The use of angiogenic factors in discriminating preeclampsia: Are they ready for prime time?

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 23, Issue 11, 2010, Pages 1294-1300

  Srinivas, Sindhu K ^a   Larkin, Jacob ^b   Sammel, Mary D ^c   Appleby, Dina ^c   Bastek, Jamie ^a   Andrela, Christina M ^a   Ofori, Ella ^a   Elovitz, Michal A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

angiogenic factors; hypertension; intra uterine growth restriction; Preeclampsia

Indexed keywords

ANGIOGENIC FACTOR; ENDOGLIN; PLACENTAL GROWTH FACTOR; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREECLAMPSIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SMALL FOR DATE INFANT; URBAN AREA;

ADULT; ANGIOGENIC PROTEINS; ANTIGENS, CD; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FETAL GROWTH RETARDATION; HUMANS; MEMBRANE PROTEINS; PRE-ECLAMPSIA; PREGNANCY; RECEPTORS, CELL SURFACE; ROC CURVE; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 77958066741     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767051003677988     Document Type: Article

References (32)

1. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Munson ML. Births: final data for 2003. Natl Vital Stat Rep 2005;54:1-116.
2. Chang J E-EL, Berg CJ, et al. Pregnancy-related mortality surveillance-United States, 1991-1999. MMWR Surveill Summ 2003;52:1-8.
3. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994;101:669-674.
4. Pijnenborg R, Dixon G, Robertson WB, Brosens I. Tropho-blastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta 1980;1:3-19.
5. Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response-a review. Placenta 2003;24 Suppl A:S21-S27.
6. Brosens I. A study of the spiral arteries of the decidua basalis in normotensive and hypertensive pregnancies. J Obstet Gynaecol Br Commonw 1964;71:222-230.
7. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of pre-eclampsia. J Pathol 1970;101:Pvi.
8. Brosens JJ, Pijnenborg R, Brosens IA. The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. Am J Obstet Gynecology 2002;187:1416-1423.
9. Genbacev O, Zhou Y, Ludlow JW, Fisher SJ. Regulation of human placental development by oxygen tension. Science 1997;277:1669-1672.
10. Ahmed A, Dunk C, Ahmad S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen-a review. Placenta 2000;21 Suppl A:S16-S24.
11. Kaufmann P, Black S, Huppertz B. Endovascular tropho-blast invasion: implications for the pathogenesis of intrauter-ine growth retardation and preeclampsia. Biol Reprod 2003;69:1-7.
12. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986;93:1049-1059.
13. Sheppard BL, Bonnar J. The ultrastructure of the arterial supply of the human placenta in pregnancy complicated by fetal growth retardation. Br J Obstet Gynaecol 1976;83:948-959.
14. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clinical Invest 2003;111:649-658.
15. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-649.
16. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683.
17. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
18. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007;197:28.e1-28.e6.
19. Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007;50:137-142.
20. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007;197:244.e1-244.e8.
21. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23.
22. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996;87:163-168.
23. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998;338: 701-705.
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
25. Shibata E, Rajakumar A, Powers RW, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neo-nates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005;90:4895-4903.
26. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004;191:1240-1246.
27. Chedraui P, Lockwood CJ, Schatz F, et al. Increased plasma soluble fms-like tyrosine kinase 1 and endoglin levels in pregnancies complicated with preeclampsia. J Matern Fetal Neonatal Med 2009:1-6.
28. Smith GC, Crossley JA, Aitken DA, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007;109:1316-1324.
29. Di Renzo GC. The role of an 'anti-angiogenic state' in complications of pregnancy. J Matern Fetal Neonatal Med 2008;21:3-7.
30. Osborne JW. Prediction in multiple regression. Prac Assess Res Eval 2000;7:1-4.
31. Janes H, Pepe MS. Adjusting for covariates in studies of diagnostic, screening, or prognostic markers: an old concept in a new setting. Am J Epidemiol 2008;168:89-97.
32. Ilekis JV, Reddy UM, Roberts JM. Preeclampsia-a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop. Reprod Sci 2007;14:508-523.